Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Maraviroc. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 known ✓ | P51681 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | KCNQ1 | P51787 | 1/20 | 1.00 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maraviroc SCHEMBL20451355 | 1.00 | CCR5 (1.00) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL4576508 | 1.00 | CCR5 (1.00) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL334506 | 1.00 | CCR5 (1.00) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL1053748 | 1.00 | CCR5 (1.00) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL2177194 | 1.00 | CCR5 (1.00) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL12611449 | 1.00 | CCR5 (1.00) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL12611504 | 0.95 | CCR5 (0.91) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL30852775 | 0.95 | CCR5 (0.91) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL12611605 | 0.95 | CCR5 (0.91) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL14168620 | 0.94 | CCR5 (0.89) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 17162 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | claimed |
| WO-2026099526-A1 | COMBINATION OF INHIBITORS OF IL-1BETA, CCR5 OR CXCR2 CYTOKINE RECEPTORS FOR USE IN THE TREATMENT OF METASTASIS | FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA (ES) | 2026-05-15 | — | — | WO | claimed |
| EP-4735033-A2 | MRNA-ENCODED TAT WITH ATTENUATED CYTOTOXICITY FOR HIV AND SIV LATENCY REVERSAL | The Trustees of the University of Pennsylvania (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| WO-2026090605-A2 | COMPOSITIONS AND METHODS COMPRISING TARGETED LIPOSOMAL THERAPEUTIC VACCINES | DREXEL UNIVERSITY (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4731611-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-29 | — | — | EP | claimed |
| US-12611453-B2 | Method of inducing an HIV-1-specific immune response using a chimpanzee adenovirus vector encoding an hivacat t-cell immunogen and TLR7 agonist | GILEAD SCIENCES, INC. (US) | 2026-04-28 | — | — | US | claimed |
| US-20260108561-A1 | COMPOSITION FOR CELL TRANSPLANTATION THERAPY AND THE USE THEREOF | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2026-04-23 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| WO-2007087548-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-08-02 | — | — | WO | claimed |
| WO-2007087549-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-08-02 | — | — | WO | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| CN-1953751-A | Combination of substituted 1-phenyl-1, 5-dihydro-pyrido- [3, 2-B ] indol-2-ones and other HIV inhibitors | TIBOTEC PHARM LTD (IE) | 2007-04-25 | — | — | CN | claimed |
| US-20070060499-A1 | Chloroquine combination drugs and methods for their synthesis | KOSAK KENNETH M | 2007-03-15 | — | — | US | claimed |
| EP-1750708-A1 | COMBINATIONS OF SUBSTITUTED 1-PHENYL-1,5-DIHYDRO-PYRIDO- [3,2-B] INDOL-2-ONES AND OTHER HIV INHIBITORS | Tibotec Pharmaceuticals Ltd. (IE) | 2007-02-14 | — | — | EP | claimed |
| WO-2006129134-A1 | SYNERGIC COMBINATIONS COMPRISING A STYRYLQUINOLINE COMPOUND AND OTHER HIV INFECTION THERAPEUTIC AGENTS | BIOALLIANCE PHARMA (FR) | 2006-12-07 | — | — | WO | claimed |
| WO-2006096444-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-14 | — | — | WO | claimed |
| WO-2005110411-A1 | COMBINATIONS OF SUBSTITUTED 1-PHENYL-1,5-DIHYDRO-PYRIDO- [3,2-B] INDOL-2-ONES AND OTHER HIV INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2005-11-24 | — | — | WO | claimed |